Galectins-1 and -3 in Human Intervertebral Disc Degeneration: Non-Uniform Distribution Profiles and Activation of Disease Markers Involving NF-κB by Galectin-1

Mahmoud Elshamly 1,2, Katharina Kinslechner, 1 Josef G. Grohs, 2 Daniela Weinmann 1, Sonja M. Walzer, 1 Reinhard Windhager, 1,2 Hans-Joachim Gabius, 3 Stefan Toegel 1,4

1Department of Orthopedics and Trauma Surgery, Karl Chiari Lab for Orthopaedic Biology, Medical University of Vienna, 1090, Vienna, Austria, 2Department of Orthopedics and Trauma Surgery, Division of Orthopedics, Medical University of Vienna, 1090, Vienna, Austria, 3Institute of Physiological Chemistry, Faculty of Veterinary Medicine, Ludwig-Maximilians University Munich, 80539, Munich, Germany, 4Ludwig Boltzmann Institute for Arthritis and Rehabilitation, Vienna, Austria

Received 7 December 2018; accepted 14 May 2019
Published online in Wiley Online Library (wileyonlinelibrary.com). DOI 10.1002/jor.24351

ABSTRACT: Degeneration of the human intervertebral disc (IVD) is assumed to underlie severe clinical symptoms, in particular chronic back pain. Since adhesion/growth-regulatory galectins are linked to arthritis/osteoarthritis pathogenesis by activating a pro-degradative-inflammatory gene expression signature, we hypothesized a similar functional involvement of galectins in IVD degeneration. Immunohistochemical evidence for the presence of galectins-1 and -3 in IVD is provided comparatively for specimens of spondylochondrosis, spondylolisthesis, and spinal deformity. Immunopositivity was detected in sections of fixed IVD specimens in each cellular compartment with age-, disease-, and galectin-type-related differences. Of note, presence of both galectins correlated with IVD degeneration, whereas correlation with age was seen only for galectin-3. In addition, staining profiles for these two galectins showed different distribution patterns in serial sections, an indication for non-redundant functionalities. In vitro, both galectins bound to IVD cells in a glycan-dependent manner. However, exclusively galectin-1 binding triggered a significant induction of functional disease markers (i.e., IL6, CXCL8, and MMP1/3/13) with involvement of the nuclear factor-kB pathway. This study thus gives direction to further network analyses and functional studies on galectins in IVD degeneration. © 2019 The Authors. Journal of Orthopaedic Research® published by Wiley Periodicals, Inc. on behalf of Orthopaedic Research Society. J Orthop Res 37:2204–2216, 2019

Keywords: anulus fibrosus; degeneration; lectin; notochord; nucleus pulposus

INTRODUCTION

Low back pain ranks among the most common medical complaints, placing an enormous burden on the individual patient, with broad-scale socioeconomic implications for our society.1,2 Although the underlying routes toward its manifestation appear complex and are not yet precisely defined, the well-documented link to degeneration of the lumbar intervertebral disc (IVD) warrants a hypothesis-driven study to relate histopathological changes to molecular characteristics.3

Obviously, identifying effectors of degeneration has potential to provide therapeutic perspective, as novel targets can initiate the development of innovative treatment modalities. In this context, it is noteworthy that cells of the nucleus pulposus (NP) have been likened to articular chondrocytes.4 Being hereby guided to look at tissue degeneration in osteoarthritis, we previously found that an emerging group of elicitors of functional disease markers in cartilage degeneration belongs to the class of endogenous lectins. In particular, we recently revealed the upregulation of distinct endogenous galectins in osteoarthritic cartilage5 and their involvement in triggering a pro-degradative-inflammatory microenvironment via expression of nuclear factor-kB (NF-kB)-regulated gene expression profiles.6–8 Mechanistically, tissue lectins “read” cellular signals encoded by glycans and translate their information into molecular activities.9,10 In osteoarthritis, members of the galectin family, that is, galectins-1, -3, and -8 (Gal-1, Gal-3, and Gal-8), serve as signaling-inducing mediators (for a recent systematic literature review on galectins in (osteo)arthritis, see Salamanna et al.11). The potential of clinical relevance in cartilage and joint degradation has led to call Gal-3 “a key player in arthritis.”12 Consequently, these proteins are receiving increasing attention, aiming to detect new connections to disease mechanisms in auto-immune regulation and beyond.13,14 This current line of investigation has prompted us to assume that galectins may also play a functional role in IVD degeneration. Indeed, the occurrence of two galectins has already been documented for degenerated tissue specimens.15–18 Thus, Gal-3—alone or in combination with CD24 and carbonic anhydrase 12—has acquired the status of an NP cell marker.19–23 Gal-1 presence was
reported in human, porcine and rat IVDs in NP and anulus fibrosus (AF) cells, in which its distribution pattern was similar to that of the matrix glycoprotein laminin (isoform LM-511), a known counterreceptor of Gal-1 and -3. Functionally, Gal-3 presence has been assumed to affect NP cell survival or “the destructive potential” of NP cells. Regulation of its expression in rat NP cells by hypoxia-inducible factor-1α or by transforming growth factor-β through canonical Smad3 signaling underscores its potential pathophysiological significance, as does its synergy with tumor necrosis factor-α on increasing levels of interleukin-1β (IL-1β), IL-6, and chemokine CCL2 gene expression factors relevant for inflammation and disc degeneration.

This study assessed three groups of clinical specimens for expression status of Gal-1 and -3, to test the hypothesis of a role of galectins in IVD degeneration. In vitro, IVD cells were additionally examined for (i) secretion of galectins, (ii) carbohydrate-inhibitable galectin binding, (iii) ensuing stimulation of transcription and secretion of selected functional disease markers and, if positive, (iv) an influence of galectins on NF-κB-dependent signaling.

MATERIALS AND METHODS

Galectins and Antibodies

Recombinant proteins, AlexaFluor-labeled galectins, and non-crossreactive antibody preparations against Gal-1 or -3 were prepared and applied as previously described in detail.

Clinical Specimens and Data

The study was approved by the ethics committee of the Medical University of Vienna (EK-No.: 1720/2015). Surgical IVD specimens were obtained with written consent from patients treated routinely with transforminal lumbar interbody fusion. Only specimens that contained all three major anatomical parts of the IVD (i.e., AF, NP, and endplate [EP]), hereby allowing histological scoring (as described below), were included in the study. The medical background of the patients covering age, sex, and diagnosis was documented. In addition, magnetic resonance imaging (MRI), computer tomography, covering age, sex, and diagnosis was documented. In addition, magnetic resonance imaging (MRI), computer tomography, and X-ray data of the patients were available, and the degree of radiological degeneration was assessed using the Pfirrmann classification. Clinical data enabled assignment of patients into three study groups, that is, spondylochondrosis, true spondylolisthesis, and spinal deformity (idiopathic scoliosis and/or kyphosis). Further details on clinical specimens are given in Method section in Supplementary Material.

Histological Assessment

IVD specimens were fixed in formalin and decalced using Titrilplex-Tris-solution, then dehydrated and embedded in paraffin according to the standard procedures. Paraffin sections (2.5 μm) were stained with hematoxylin and eosin (HE; for morphological evaluation) or Safranin O (SO; for evaluation of glycosaminoglycan content), counterstained using light green Goldner III solution. The degree of degeneration was graded by microscopic evaluation of the sections according to an established histological scoring system with minor modifications. In brief, presentation of the major anatomical structures of the IVD (i.e., EP, AF, AF/NP boundaries, NP cells, and matrix) as well as IVD staining with SO were included in the analysis. In each subcategory, the level of degeneration was scored as 0, 1, or 2, based on defined histological characteristics. Summing up the six individual scores, a total histological score of degeneration was computed, ranging from 0 (intact IVD) to 12 (most strongly degenerated IVD). The histological grading was performed independently by two observers. Cases of deviating assessments were discussed to reach agreement.

Immunohistochemistry

Immunohistochemical processing and semiquantitative analysis followed a standardized protocol using non-cross-reactive antibody preparations.

Isolation and Culture of IVD Cells

Primary human IVD cells were isolated following published protocols. In brief, IVD specimens were obtained from eight patients (11 spinal levels, age 32–70 years, five female, three male) undergoing spinal surgery due to spondylochondrosis (n = 7 patients) or spondylolisthesis (n = 1). Disc tissues were separated from EPs, rinsed with phosphate-buffered saline (PBS) and cut into small pieces, which were treated enzymatically using a 0.2% (w/v) solution of collagenase overnight at 37°C. IVD cells were cultured thereafter in growth medium consisting of Dulbecco’s modified Eagle’s medium supplemented with 10% fetal calf serum, penicillin (50 units/ml), streptomycin (50 μg/ml), and amphotericin B (25 μg/ml). Cultures were kept at 37°C in a humidified atmosphere with 5% CO2 and used for experiments at passage 1. Following overnight starvation, cells were exposed in absence or presence of 40 μM CAPE (Merck, Darmstadt, Germany)—for 24 h to 10 μg/ml Gal-1, 18 μg/ml Gal-3 or with a mixture thereof prior to analysis using quantitative reverse-transcription polymerase chain reaction (RT-qPCR). For western blot experiments, cells were incubated with 10 μg/ml Gal-1 for 15 min.

Detection of Galectin-Binding Sites on the Surface of IVD Cells

Following previously established protocols, cultured IVD cells (n = 4 patients) were harvested by trypsinization, and a cell suspension of 3 × 10^6 cells in 50 μl PBS was incubated with a mixture of AlexaFluor555-labeled Gal-1 (1 μg/50 μl) and AlexaFluor488-labeled Gal-3 (2 μg/50 μl) for 10 min at 4°C, in the presence or absence of 0.1 M lactose to control for inhibition by cognate glycan. Images were immediately taken without fixation using laser scanning microscopy (Carl Zeiss, Oberkochen, Germany; LSM700; Zen software).

RT-qPCR

Isolation of total RNA, complementary DNA synthesis, and SYBR-green-based qPCR experiments were performed as previously described. A detailed checklist containing all relevant information is provided in Supplementary Table S1. Messenger RNA (mRNA) levels were calculated as relative quantities compared to the untreated controls considering amplification efficiencies and normalization to succinate dehydrogenase complex, subunit A (SDHA).
Enzyme-Linked Immunosorbent Assays (ELISAs)
The levels of pro-MMP-1, pro-MMP-13, and total-MMP-3 were
detected in cell culture supernatants of Gal-1- or Gal-3-
treated IVD cells (all ELISAs; R&D Systems, Minneapolis,
MN). Supernatants of untreated IVD cells served as controls.
Also, supernatants of untreated IVD cells were processed for
galactin secretion (ELISAs from R&D Systems). Ranges of
standard curve were 0.313–20 ng/ml for Gal-1, 0.157–10 ng/ml
for Gal-3, 0.157–10 ng/ml for pro-MMP-1 and total-MMP-3,
and 78–5,000 pg/ml for pro-MMP-13.

Western Blot
Western blot analyses were performed as previously
described. Briefly, membranes (nitrocellulose blotting mem-
brane 0.2 μm; GE Healthcare Life Sciences, Freiburg, Ger-
many) were incubated for 2 h with primary antibodies specific
for phospho NF-κB p65 (Ser536; 1:1,000; rabbit monoclonal;
Cell Signaling, Danvers, MA), NF-κB p65 (1:1,000; mouse
monoclonal; Cell Signaling), and β-actin (1:5,000; mouse
monoclonal; Cell Signaling). Thereafter, membranes were
incubated for 1 h with a solution containing IRDye 800CW
goat anti-rabbit IgG (1:15,000; LI-COR, Bad Homburg,
Germany) and IRDye 680LT goat anti-mouse IgG (1:15,000;
LI-COR, Bad Homburg, Germany). Signal intensities were
quantified using the Odyssey Imager CLx (LI-COR, Bad
Homburg, Germany). The ratios between levels of phospho-
p65 and total p65 (both normalized to β-actin) were calcu-
lated and depicted as absolute signal intensities.

Statistics
Data were analyzed using IBM (Armonk, NY) SPSS v25 with
descriptive statistics, parametric, and non-parametric inferential
statistics, as well as Spearman correlation analyses, where r
values were interpreted as follows: 0–0.2: weak correlation,
>0.2–0.4: mild correlation, >0.4–0.6: moderate correlation,
>0.6–0.8: moderately strong correlation, and >0.8–1: strong
correlation. Kruskal–Wallis test (with pairwise comparison) was
used for comparing the differences in median values of certain
parameters between the disease groups, while Friedman test
(with pairwise comparison) was used to compare the median
values of different parameters within the same group. The qPCR
data were analyzed using Wilcoxon or Friedman tests with
pairwise comparison. Significance values were adjusted by
Bonferroni correction for multiple comparisons.

RESULTS
Clinical and Histological Classification of IVD Specimens
After having rigorously tested the clinical material
regarding its suitability for histological scoring, speci-
mens from 23 patients with spondylochondrosis, eight
patients with spondylolisthesis, and seven patients
with spinal deformity could be included into this study.
Details on the patients’ age, sex, and the Pfirrmann
grades of IVDs are given in Table 1. To document the
morphological status, exemplary T2-weighted MRI
data from representative patients of each group are
presented in Supplementary Figure S1a.

Supplementary Figure S1b shows histological
IVD sections from representative specimens of each
of the three cohorts stained with HE or SO. Comparison of total histological scores revealed
that spondylochondrosis specimens had significantly
higher median scores than spondylolisthesis
or deformity specimens (p < 0.05; Supplementary
Figure S1c). As shown in Supplementary Table S2,
histological alterations in all six histological sub-
categories contributed to a significant difference
between spondylochondrosis and either spondylolisthesis or deformity specimens.

When all data were combined, a moderately strong
correlation (r = 0.783, p < 0.0001) between histological
score and Pfirrmann grade was found (Supplementary
Figure S1d). Taken together, the analyzed IVD specimens
provided a solid basis for immunohistochemical analyses.

Immunohistochemical Localization of Gal-1 in
Degenerated IVD
The percentages of Gal-1 positivity in EP, AF, cells, or
matrix of the NP as well as the AF/NP boundary were
determined microscopically. Figure 1A shows staining

Table 1. Demographics and Patients’ Characteristics

| Parameter                  | Spondylochondrosis | Spondylolisthesis | Deformity   | Kruskal–Wallis test |
|----------------------------|--------------------|-------------------|-------------|---------------------|
| Number (female/male)       | n = 23             | n = 8             | n = 7       |                     |
| F = 16/M = 7               | F = 6/M = 2        | F = 3/M = 4       |             |                     |
| Levels                     | L2–3 (n = 3)       | L5–S1 (n = 8)     | Th11–12 (n = 1) |                     |
| L3–4 (n = 4)               | Th11–12 (n = 1)    |                  |             |                     |
| L4–5 (n = 8)               | L3–4 (n = 1)       |                  |             |                     |
| L5–S1 (n = 8)              | L4–5 (n = 1)       |                  |             |                     |
| Age (years; mean ± SD)     | 58.8 ± 11.4        | 37.4 ± 9.4        | 33.2 ± 19.7 | 0.005<sup>a</sup>   |
| Pfirrmann score (median ± IQ range) | 4 ± 1          | 3 ± 3            | 1.5 ± 1     | 0.02<sup>b</sup>    |

Shown are the p values of Kruskal–Wallis test for age and the Pfirrmann score between the three cohorts:
<sup>a</sup>Spondylochondrosis versus spondylolisthesis.
<sup>b</sup>Spondylochondrosis versus deformity.
<sup>c</sup>Spondylolisthesis versus deformity.
for Gal-1 in histological IVD sections from representative patients. Nuclei, cytoplasm (particularly in cells of large chondrons) as well as pericellular and the extracellular matrix were immunopositive (Fig. 2).

The median total Gal-1 LI scores (±IQ range) were 8 ± 5 in the spondylochondrosis cohort, 4.5 ± 1.75 in the spondylolisthesis cohort and 6 ± 7 in the deformity cohort. Within the spondylochondrosis specimens, the extent of

Figure 1. Immunohistochemically detected presence of Gal-1 in clinical intervertebral disc (IVD) specimens and its correlation with clinical and histological signs of degeneration. (A) Shown are representative IVD specimens from patients of the spondylochondrosis (left column), the spondylolisthesis (middle column), and the deformity cohorts (right column). The Gal-1 positivity (brown color) among cells in the endplate (EP), the anulus fibrous (AP), the boundary region between AP and NP (AP/NP), as well as for cells or matrix of the nucleus pulposus (NP) is documented. Scale bars = 50 or 200 µm (NP matrix). (B) Comparison of total Gal-1 LI scores between patients of the spondylochondrosis, spondylolisthesis, and deformity cohorts. Results are presented as dotplots showing Gal-1 LI scores for patients of each cohort. The median values are indicated as bars. *p < 0.05 (Kruskal–Wallis test). (C,D) Shown are scatterplots of total Gal-1 LI scores versus (C) histological IVD scores or (D) Pfirrmann grades for patients of all three cohorts with the regression line. The Spearman correlation coefficient r and the p value (bivariate correlation test) were calculated given in this panel. [Color figure can be viewed at wileyonlinelibrary.com]

Figure 2. Immunohistochemically detected presence of Gal-1 and Gal-3 in clinical intervertebral disc (IVD) specimens at different sites, that is, nuclear and cytoplasmic positivity and staining of pericellular and extracellular matrix. Negative controls in absence of primary antibodies are shown for all sites. Scale bars = 50 µm. [Color figure can be viewed at wileyonlinelibrary.com]
|                  | Spondylochondrosis (Median ± IQR) | Spondylolisthesis (Median ± IQR) | Deformity (Median ± IQR) | Kruskal–Wallis Test | Overall Median ± IQR |
|------------------|-----------------------------------|----------------------------------|--------------------------|---------------------|----------------------|
| EP               | 0 ± 1                             | 0 ± 0                            | 0 ± 0                    | >0.05<sup>a</sup>   | 0 ± 1                |
| AF               | 2 ± 2                             | 1 ± 0                            | 1 ± 2                    | >0.05<sup>a</sup>   | 1 ± 1                |
| AF/NP            | 2 ± 3                             | 2 ± 1                            | 1 ± 2                    | >0.05<sup>a</sup>   | 1.5 ± 1              |
| NP cells         | 3 ± 2                             | 1 ± 1.75                         | 2 ± 2                    | >0.05<sup>a</sup>   | 2 ± 2                |
| NP matrix        | 1 ± 2                             | 0 ± 1                            | 1 ± 3                    | >0.05<sup>a</sup>   | 0.5 ± 2              |
| Total Gal-1 score | 8 ± 5                           | 4.5 ± 1.75                      | 6 ± 7                    | >0.05<sup>a</sup>   | 6 ± 6                |

**Friedman test**

- Pairwise comparison:
  - EP vs. AF, $p = 0.01$
  - EP vs. AF/NP, $p = 0.01$
  - EP vs. NP cells, $p = 0.001$
  - AF/NP vs. NP cells, $p = 0.007$
  - AF vs. NP cells, $p = 0.0001$

AF, anulus fibrosus; EP, endplate; IQR, interquartile range; IVD, intervertebral disc; NP, nucleus pulposus.

Shown are the median values (±IQR) of Gal-1 positivity scores in EP, AF, AF/NP, and NP cells and in NP matrix as well as the total Gal-1 positivity scores for all three cohorts. In addition, $p$ values of the Friedman test (with pairwise comparison and Bonferroni correction) between the different components of the IVD within a cohort are presented.

<sup>a</sup>Spondylochondrosis versus spondylolisthesis.

<sup>b</sup>Spondylochondrosis versus deformity.

<sup>c</sup>Spondylolisthesis versus deformity.
Gal-1 positivity was significantly higher in cells of the AF and the NP than in cells of the EP (p = 0.01 and p = 0.001, respectively; Table 2). Within the spondylolisthesis specimens, level of Gal-1 positivity was significantly higher in cells of the AF/NP boundary region than in cells of the EP (p = 0.01; Table 2), whereas it was significantly higher in NP cells than in EP cells in deformity specimens (p = 0.01; Table 2).

Comparison of total Gal-1 LI scores revealed no statistically significant difference between the three cohorts (p > 0.05; Fig. 1B and Table 2). Table 2 further shows that the three study groups did not significantly differ in Gal-1 LI scores in subcategories.

Correlation analyses of all specimens, irrespective of the assigned study group, revealed a moderate correlation between total Gal-1 LI and histological scores (r = 0.531, p < 0.001; Fig. 1C) and a mild correlation between total Gal-1 LI score and Pfirrmann grade (r = 0.387, p = 0.022; Fig. 1D).

Immunohistochemical Localization of Gal-3 in the Degenerated IVD

Figure 3A illustrates immunopositivity for Gal-3 in histological IVD sections from representative patients of the three cohorts. Similarly to Gal-1, Gal-3 was present in the four main sites, with a tendency for comparatively intense staining in the pericellular matrix (Fig. 2). The medians of total Gal-3 LI scores (±IQ range) were 12 ± 10 in the spondylochondrosis cohort, 5 ± 5.57 in the spondylolisthesis cohort and 5 ± 11 in the deformity cohort.

Within the spondylochondrosis specimens, the level of Gal-3 positivity was higher in NP cells than in EP cells and NP matrix (p = 0.008 and p = 0.03, respectively; Table 3). However, there were no significant differences in Gal-3 positivity across the different IVD components within spondylolisthesis or deformity specimens (p > 0.05; Table 3).

Comparison of total Gal-3 LI scores across the three study groups revealed no statistically significant difference (p > 0.05; Fig. 3B and Table 3). However, as presented in Table 3, Gal-3 positivity of NP cells in spondylochondrosis specimens was significantly higher than that of NP cells in spondylolisthesis specimens (p = 0.02).

Further correlation analyses of all specimens, irrespective of the assigned study group, revealed a moderate degree of correlation of total Gal-3 LI scores with historical scores (r = 0.564, p < 0.0001; Fig. 3C) or the Pfirrmann grades (r = 0.465, p = 0.006; Fig. 3D), respectively.

Correlation Analyses for Age and Total Gal-1/Gal-3 Scores

Analyses revealed a moderate degree of correlation of age with the Pfirrmann grade (r = 0.577, p < 0.001; Fig. 4A), the historical score (r = 0.470, p = 0.003; Fig. 4B),...
### Table 3. Immunohistochemical Scores of Gal-3 Positivity

|                | Spondylochondrosis (Median ± IQR) | Spondylolisthesis (Median ± IQR) | Deformity (Median ± IQR) | Kruskal–Wallis Test | Overall Median ± IQR |
|----------------|-----------------------------------|----------------------------------|--------------------------|---------------------|----------------------|
| EP             | 1 ± 1                             | 1 ± 1                            | 1 ± 1                    | >0.05^a             | 1 ± 1                |
| AF             | 3 ± 3                             | 1 ± 1                            | 1 ± 3                    | >0.05^a             | 2 ± 2                |
| AF/NP          | 2 ± 3                             | 1 ± 0.75                         | 1 ± 3                    | >0.05^a             | 1 ± 2                |
| NP cells       | 3 ± 3                             | 1 ± 1.75                         | 1 ± 3                    | 0.02^a              | 3 ± 2                |
| NP matrix      | 1 ± 2                             | 1 ± 1                            | 1 ± 1                    | >0.05^a             | 1 ± 1                |
| Total Gal-3 score | 12 ± 10                           | 5 ± 5.75                         | 5 ± 11                   | >0.05^a             | 9 ± 8                |

Friedman test (pairwise comparison)  
- p = 0.008 (EP vs. NP cells)  
- p = 0.03 (NP cells vs. NP matrix)  
- p = 0.018 (EP vs. AF/NP)  
- p < 0.008 (EP vs. AF)  
- p < 0.0001 (EP vs. NP cells)  
- p = 0.029 (NP matrix vs. NP cells)

AF, anulus fibrosus; EP, endplate; IQR, interquartile range; IVD, intervertebral disc; NP, nucleus pulposus.

Shown are the median values (±IQR) of Gal-3 positivity scores in EP, AF, AF/NP, and NP cells and in NP matrix as well as the total Gal-3 positivity scores for all three cohorts. In addition, p values of the Friedman test (with pairwise comparison and Bonferroni correction) between the different components of the IVD within a cohort are presented.

^a Spondylochondrosis versus spondylolisthesis.

^b Spondylochondrosis versus deformity.

^c Spondylolisthesis versus deformity.
and the total Gal-3 LI score ($r = 0.448$, $p = 0.005$; Fig. 4D). In contrast, however, there was no significant correlation between age and the total Gal-1 LI score ($r = 0.074$, $p > 0.05$; Fig. 4C). Of note, there was also no marked correlation between the total LI scores of Gal-1 and Gal-3 (Fig. 5A). Figure 5B shows representative specimens of donors with different level of positivity for Gal-1 and for Gal-3, as documented in Figure 5A. Processing serial sections of the three selected IVD specimens immunohistochemically with solutions containing antibodies against Gal-1 or Gal-3, respectively, and performing microscopic evaluation of NP cells, variability of staining profiles was observed in pairwise comparison. Shown are representative specimens with different extents of immunohistochemical cell labeling, that is, with 75–100% positivity for both Gal-1 and Gal-3, with 75–100% positivity for Gal-1 and <25% positivity for Gal-3 and with <25% positivity for Gal-1 and 75–100% positivity for Gal-3 (Fig. 5B). Together, these panels suggest that the extent of positivity of NP cells for these two galectins is not strictly co-regulated in the degenerated IVD.

**Galectin-Mediated Effects on Functional Disease Markers in Isolated IVD Cells**

First, qPCR analysis detected LGALS1- and LGALS3-specific mRNAs (encoding Gal-1 and Gal-3, respectively) in isolated IVD cells at passage 1. LGALS1 ($19.4 \pm 9.3$ molecules/molecules SDHA) was expressed at significantly higher levels than LGALS3 ($7.3 \pm 0.8$ molecules/molecules SDHA, $p < 0.05$; Wilcoxon test; $n = 5$ discs from four patients). In agreement, Gal-1 and -3 were found in supernatants of IVD cells at concentrations of $10.5 \pm 3.7$ and $1.0 \pm 0.4$ ng/ml, respectively ($n = 8$ discs from six patients; $p < 0.05$, Wilcoxon test). Thus, IVD cells actively secrete these two galectins into the medium, where they can act as auto- and/or paracrine factors, if capable to bind to the cell surface. To test for galectin binding, fluorescent galectins were used, allowing two-color staining. When applying a mixture of labeled Gal-1 and -3 on viable IVD cells at 4°C ($n = 4$ patients), strong staining of cellular membranes was observed (Fig. 6). Presence of cognate sugar (lactose) precluded binding (not shown).

Aiming to probe into post-binding signaling, qPCR assays identified Gal-1 as a potent inducer of functional disease markers in IVD cells (Fig. 7). In detail, IL6 (median ± IQR: $10.6 \pm 26.6$-fold, $p = 0.006$; Fig. 7A), CXCL8 ($75.0 \pm 46.8$-fold, $p = 0.011$; Fig. 7B), IL1B ($2.9 \pm 36.8$-fold, $p = 0.058$; Fig. 7C) as well as MMP1 ($82.3 \pm 145.4$-fold, $p = 0.011$; Fig. 7D), MMP3 ($33.7 \pm 39.7$-fold, $p = 0.004$; Fig. 7E) and MMP13 ($3.0 \pm 2.7$-fold, $p = 0.137$; Fig. 7F) were upregulated.

**Figure 4.** Correlation of clinical and immunohistochemical scores with age of patients. Shown are scatterplots of the patients’ age (from the three cohorts) versus (A) Pfirrmann grades, (B) histological IVD scores, (C) total Gal-1 LI scores, and (D) total Gal-3 LI scores. Regression lines, Spearman coefficients ($r$) and $p$ values are provided.
after exposure to 10 µg/ml Gal-1 in seven IVD cell populations isolated from five patients. In contrast, Gal-3 (18 µg/ml; equimolar in monomeric units) did not cause significant effects on any of the analyzed marker genes in the same cell populations (Fig. 7A–F). Increasing the concentration of Gal-3 to 90 µg/ml did not significantly upregulate these markers (Wilcoxon test, n = 3 patients): IL6 (median: 4.5-fold, p = 0.109), CXCL8 (6.9-fold, p = 0.109), IL1B (2.4-fold, p = 0.285) as well as MMP1 (6.8-fold, p = 0.109), MMP3 (4.0-fold, p = 0.285), and MMP13 (1.7-fold, p = 0.109). To investigate the effects of a combined treatment, IVD cells were treated with a mixture of Gal-1 (10 µg/ml) and Gal-3 (18 µg/ml). This resulted in upregulation of gene expression comparable to that induced by Gal-1 alone (Fig. 7A–F). Another common marker for degradation, ADAMTS5, in contrast, was not significantly modified by Gal-1 and Gal-3, alone or in combination (data not shown). Preliminary evidence on testing separated AF and NP cell populations of a single patient indicates possibility for differences in relative degree of responsiveness to galectin exposure with respect to type of target gene and cell type (data not shown).

In agreement with qPCR data, ELISAs revealed an induction by Gal-1 of pro-MMP-1, total MMP-3, and pro-MMP-13 secretion in IVD cells, whereas Gal-3 did not affect the secretion of these markers (Fig. 7G–I). On the basis of previous experience with Gal-1 and osteoarthritic chondrocytes, western blot assays were performed to trace involvement of the NF-κB-dependent signaling pathway. Figure 8A shows that incubation with 10 µg/ml Gal-1 for 15 min resulted in a mild increase of p65 phosphorylation in all three tested IVD cell populations isolated from different patients. In quantitative terms, the extent of phospho-p65 upregulation ranged between 10% and 90% (mean ± SD: 43 ± 42%, n = 3), when data were normalized to total p65 and β-actin as loading control (Fig. 8B). Fittingly, CAPE (an inhibitor of NF-κB translocation into the nucleus) markedly reduced mRNA levels of the marker genes IL6, IL1B, MMP1, and MMP3 in IVD cells to a range of about 12–47% (Fig. 8C).

**DISCUSSION**

The multifunctionality of galectins argues in favor of thorough localization studies in combination with...
functional testing, to uncover their relevance for disease manifestation. Also, the emerging concept of teamwork among galectins, initially tested in mixtures of Gal-1 and -3 leading to detection of antagonism or cooperation, suggests to map expression profiles beyond a single family member. In this report, we characterized the distribution profiles of Gal-1 and -3 in human IVD degeneration. Of note, common absence of a signal peptide explains their intracellular positivity, exemplarily documented in Figure 2. Of clinical relevance, galectins occurred extracellularly in tissue sections and in supernatants of primary cultures, and galectins bound to IVD cells and had a different impact on expression of functional disease markers.

Our study followed a stepwise design. First, we collected clinical IVD specimens of three different spinal diseases. In agreement with previous reports, the histopathological degeneration scores of the IVD specimens significantly correlated with MRI-based grading, thus supporting the eligibility of the included clinical specimens and the histological scoring. Our results further revealed that proteoglycan content (SO staining) and NP cells were generally more affected by disease progression than the EP, the NP matrix, the AF, and—in terms of the proteoglycan content—than the AF/NP boundary.

Having thus obtained an overview of the clinical material, the immunohistochemical analyses revealed positivity for Gal-1 in NP (both cells and matrix), the AF and the AF/NP boundary. Matrix positivity is (patho)physiologically relevant, because presentation of Gal-1 by a mixture of extracellular matrix components (Matrigel) decreased the required quantity for its T cell death-inducing capacity by one order of magnitude as compared to Gal-1 in solution. Whereas chondrocytes of the EP were rarely positive for Gal-1, comparable extent of Gal-1 presence was found in cells of the AF and NP. Our data thus extend a previous report on Gal-1 localization in IVDs of lumbar spine of a human adult with no spinal pathology (age: 35 years), by considering degenerated tissues and a comprehensive analysis of all IVD compartments.

By adding data on Gal-3 localization, we further initiated the monitoring of more than one galectin in specimens of degenerated IVDs. Immunopositivity for Gal-3 was detected in the NP, and also in the other compartments. Its presence within the cells and in the matrix supports the concept of site-specific activities, for example via its anti-apoptotic intracellular and glycan-dependent extracellular mechanisms involving Gal-3-mediated counterreceptor aggregation. A respective impact on chondrocyte survival was inferred by localization studies considering hypertrophy and in a knock-out model, as also suggested for Gal-3 in osteoarthritis. In rat NP cells, Gal-3 knock-down led to increased susceptibility to FasL-induced cell death, and a functional cooperation between tumor necrosis factor-α and Gal-3 on IL-1α, IL-6, and CCL2 expression had been reported. Considering initial evidence for functional networking among galectins, it becomes reasonable that upcoming studies proceed with the immunohistochemical analysis of further members of this lectin family (such as Gal-8), at best reaching the level of comprehensive fingerprinting.

When setting the distribution profiles of Gal-1 and -3 in relation to tissue degradation, the total scores of immunopositivity significantly correlated with histopathological degeneration and MRI grading. At the level of IVD components, immunopositivity for Gal-1 and -3 at all sites, except for EP and the NP matrix in the case of Gal-1, independently correlated with total histopathological degeneration scores of the specimens. However, although histopathological degeneration (and partly MRI scores) differed between the three cohorts, immunohistochemical staining scores for Gal-1 and -3 were similar.

Age is a critical factor for the degeneration of the IVD, both in terms of tissue structure and biochemical composition, as also reflected by our collection of specimens. Concerning the studied galectins, Gal-3 presence significantly correlated with age. Age-related changes of Gal-3 expression have already been documented in the developing human vertebral column and in a comparison of NP cells between young (29–39 years) and mature (40–59 years) adults. In contrast, Gal-1 expression—that significantly correlated with histopathological and MRI-based evidence for degeneration—did not correlate with patient age. This observation points to the possibility that Gal-1 may...
qualify as functional disease marker, warranting efforts to design and test highly specific antagonists such as the recently reported Gal-3-like Gal-1 variant.49 As illustrated by work in vitro, Gal-1 was secreted by IVD cells, bound to their surface and proved active as elicitor of functional disease markers. In contrast, tested in parallel or as part of a mixture (at concentrations previously defined to be active for osteoarthritic chondrocytes7,8), Gal-3 failed to induce expression of relevant genes, thus revealing functional divergence between these two galectins. In agreement, Gal-1’s immunopositivity profile in serial sections did not consistently match Gal-3 distribution, further arguing against a functional similarity as observed in osteoarthritic chondrocytes.7

In summary, our study characterized the distribution profiles of Gal-1 and -3 in the degenerated IVD, thereby establishing the basis for further galectin monitoring in IVD degeneration and supporting the concept of sugar code-driven mechanisms in common diseases.10 Cell-based experiments describe functional divergence between these two galectins, highlighting homodimeric Gal-1 as stimulator of disease marker expression, likely via NF-kB signaling. Of note,
Figure 8. Effects of Gal-1 and Gal-3 on the extent of phosphorylation of p65 in intervertebral disc (IVD) cells and nuclear factor-κB (NF-κB)-responsive genes. IVD cells from three patients (P1-3) in passage 1 were treated with 10 µg/ml Gal-1 for 15 min. (A) Shown are blots of extracts obtained from three patients for detection of phosphorylated p65, total p65, and β-actin. (B) Ratios between phosphorylated p65 and total p65 (both normalized to β-actin), were calculated and depicted as absolute signal intensities. (C) IVD cells (n = 2 patients) were treated for 24 h with 10 µg/ml Gal-1 and 40 µM CAPE. Quantitative reverse-transcription polymerase chain reaction (RT-qPCR) analyses of IL6, IL1B, MMP1, and MMP3 messenger RNA (mRNA) levels were performed. The graphs show the percentage of Gal-1 activity in the absence (equals 100%) and presence of CAPE. [Color figure can be viewed at wileyonlinelibrary.com]

modular architecture and glycan fine-specificity differ for these two galectins. The strategy to evaluate galectin expression beyond a single protein gives further work a clear direction, that is, to monitor the presence and function of tandem-repeat-type galectins such as Gal-8 and to examine antagonist potency of newly engineered galectin variants.

AUTHORS’ CONTRIBUTION
ST, JGG, and HJG conceived and designed the study. JGG and RW provided the clinical specimens. ME, KK, DW, SMW, and ST performed the experiments. ST and HJG wrote the manuscript with contributions by ME and KK. All authors analyzed and interpreted the data. All authors discussed, revised, and approved the final manuscript.

ACKNOWLEDGMENTS
The authors sincerely thank the reviewers for their valuable input as well as Melanie Cezanne, Melanie Schmid, and Ruth Gruebl-Barabas for excellent technical assistance. Stefan Toegel acknowledges generous funding by the Association for Orthopedic Research (AFOR) Foundation.

REFERENCES
1. Andersson GB. 1999. Epidemiological features of chronic low-back pain. Lancet 354:581–585.
2. Taylor VM, Deyo RA, Cherkin DC, Kreuter W. 1994. Low back pain hospitalization. Recent United States trends and regional variations. Spine 19:1207–1212.
3. Dowdell J, Erwin M, Choma T, et al. 2017. Intervertebral disk degeneration and repair. Neurosurgery 80:S46–S54.
4. Sive JI, Baird P, Jeziorski M, et al. 2002. Expression of chondrocyte markers by cells of normal and degenerate intervertebral discs. Mol Pathol 55:91–97.
5. Toegel S, Bieder D, André S, et al. 2014. Human osteoarthritic knee cartilage: fingerprinting of adhesion/growth-regulatory galectins in vitro and in situ indicates differential upregulation in severe degeneration. Histochem Cell Biol 142:373–388.
6. Toegel S, Weinmann D, André S, et al. 2016. Galectin-1 couples glyobiology to inflammation in osteoarthritis through the activation of an NF-κB-regulated gene network. J Immunol 196:1910–1921.
7. Weinmann D, Schlangen K, André S, et al. 2016. Galectin-3 induces a pro-degradative/inflammatory gene signature in human chondrocytes, teaming up with galectin-1 in osteoarthritis pathogenesis. Sci Rep 6:39112.
8. Weinmann D, Kenn M, Schmidt S, et al. 2018. Galectin-8 induces functional disease markers in human osteoarthritis and cooperates with galectins-1 and -3. Cell Mol Life Sci 75:4187–4205.
9. Gabius H-J, Roth J. 2017. An introduction to the sugar code. Histochem Cell Biol 147:111–117.
10. Manning JC, Romero A, Habermann FA, et al. 2017. Lectins: a primer for histochemists and cell biologists. Histochem Cell Biol 147:199–222.
11. Salamanna F, Veronesi F, Frizziero A, Fini M. 2019. Role and translational implication of galectins in arthritis pathophysiology and treatment: a systematic literature review. J Cell Physiol 234:1588–1605.
12. Hu Y, Yéléhé-Okouma M, Ea H-K, et al. 2017. Galectin-3: a key player in arthritis. Joint Bone Spine 84:15–20.
13. Kaltner H, Toegel S, Caballero GG, et al. 2017. Galectins: their network and roles in immunity/tumor growth control. Histochem Cell Biol 147:239–256.
14. Kasai K. 2018. Galectins: quadruple-faced proteins. Trends Glycosci Glycotechnol 30:SE221–SE223.
15. Poirier F, Timmons PM, Chan CT, et al. 1992. Expression of the L14 lectin during mouse embryogenesis suggests multiple roles during pre- and post-implantation development. Development 115:143–155.
16. Fowlis D, Colnot C, Ripoche MA, Poirier F. 1995. Galectin-3 is expressed in the notochord, developing bones, and skin of the postimplantation mouse embryo. Dev Dyn 203:241–251.
17. Götz W, Kasper M, Miosge N, Hughes RC. 1997. Detection and distribution of the carbohydrate binding protein galectin-
3 in human notochord, intervertebral disc and chordoma. Differentiation 62:149–157.

18. van den Brûle FA, Fernandez PL, Buicu C, et al. 1997. Differential expression of galectin-1 and galectin-3 during first trimester human embryogenesis. Dev Dyn 209:399–405.

19. Hunter CJ, Matyas JR, Duncan NA. 2003. The notochordal cell in the nucleus pulposus: a review in the context of tissue engineering. Tissue Eng 9:667–677.

20. Oguz E, Tsai T-T, Di Martino A, et al. 2007. Galectin-3 expression in the intervertebral disc: a useful marker of the notochord phenotype? Spine 32:9–16.

21. Weiler C, Nerlich AG, Schaaf R, et al. 2010. Immunohistochemical identification of notochordal markers in cells in the aging human lumbar intervertebral disc. Eur Spine J 19:1761–1770.

22. Hirata H, Yurube T, Kakutani K, et al. 2014. A rat tail temporary static compression model reproduces different stages of intervertebral disc degeneration with decreased notochordal cell phenotype. J Orthop Res 32:455–463.

23. Richardson SM, Ludwinski FE, Gnanaalingham KK, et al. 2017. Notochordal and nucleus pulposus marker expression is maintained by sub-populations of adult human nucleus pulposus cells through aging and degeneration. Sci Rep 7:13556.

24. Chen J, Jing L, Gilchrist CL, et al. 2012. Differential expression of galectin-3 and their ligands in tumor biology. Non Cancer Res 1861–1865.

25. Jing L, So S, Lim SW, et al. 2012. Differential expression of galectin-1 and its interactions with cells and laminins in the intervertebral disc. J Orthop Res 30:1923–1931.

26. Ohannesian DW, Lotan D, Thomas P, et al. 1995. Carcinobryonic antigen and other glycoconjugates act as ligands for galectin-3 in human colon carcinoma cells. Cancer Res 55: 2191–2199.

27. André S, Kojima S, Yamazaki N, et al. 1999. Galectins-1 and -3 and their ligands in tumor biology. Non-uniform properties in cell-surface presentation and modulation of adhesion to matrix glycoproteins for various tumor cell lines, in biodistribution of free and liposome-bound galectins and in their expression by breast and colorectal carcinomas with/without metastatic propensity. J Cancer Res Clin Oncol 125:461–474.

28. Zeng Y, Danielson KG, Albert TJ, et al. 2007. HIF-1 alpha is a regulator of galectin-3 expression in the intervertebral disc. J Bone Miner Res 22:1851–1861.

29. Tian Y, Yuan W, Li J, et al. 2016. TGFβ regulates galectin-3 expression through canonical Smad3 signaling pathway in nucleus pulposus cells: implications in intervertebral disc degeneration. Matrix Biol 50:39–52.

30. Risbud MV, Shapiro IM. 2014. Role of cytokines in intervertebral disc degeneration: pain and disc content. Nat Rev Rheumatol 10(1):44–56.

31. Wang X, Wang H, Yang H, et al. 2014. Tumor necrosis factor-α- and interleukin-1β-dependent matrix metalloproteinase-3 expression in nucleus pulposus cells requires cooperative signaling via syndecan 4 and mitogen-activated protein kinase-NF-κB axis: implications in inflammatory disc disease. Am J Pathol 184:2560–2572.

32. Kaltner H, Seyrek K, Heck A, et al. 2002. Galectin-1 and galectin-3 in fetal development of bovine respiratory and digestive tracts. Comparison of cell type-specific expression profiles and subcellular localization. Cell Tissue Res 307:35–46.

33. Pfirrmann CW, Metzdorf A, Zanetti M, et al. 2001. Magnetic resonance classification of lumbar intervertebral disc degeneration: pain and disc content. Nat Rev Rheumatol 10(1):44–56.

34. Rutgees JPHJ, Duit RA, Kummer JA, et al. 2013. A validated new histological classification for intervertebral disc degeneration. Osteoarthritis Cartilage 21:2039–2047.

35. Tianen AN, Klawitter M, Lux V, et al. 2012. Detrimental role for human high temperature requirement protease A1 (HTRA1) in the pathogenesis of intervertebral disc (IVD) degeneration. J Biol Chem 287:21335–21345.

36. Toegel S, Bieder D, André S, et al. 2013. Glycophenotyping of osteoarthritic cartilage and chondrocytes by RT-qPCR, mass spectrometry, histochemistry with plant/human lectins and lectin localization with a glycoprotein. Arthritis Res Ther 15:R147.

37. Bustin SA, Beaulieu J-F, Huggett J, et al. 2010. MIQE précé: practical implementation of minimum standard guidelines for fluorescence-based quantitative real-time PCR experiments. BMC Mol Biol 11:74.

38. Xiao Q, Ludwig A-K, Romanò C, et al. 2018. Exploring functional pairing between surface glycocojugates and human galectins using programmable glycodendrimersomes. Proc Natl Acad Sci USA 116:E2509–E2518.

39. Canbay S, Turhan N, Bozkurt M, et al. 2013. Correlation of matrix metalloproteinase-3 expression with patient age, magnetic resonance imaging and histopathological grade in lumbar disc degeneration. Turk Neurosurg 23:427–433.

40. Gozgoris A, Batistatou A, Alexiou GA, et al. 2011. Correlation of matrix metalloproteinases-1 and -3 with patient age and grade of lumbar disc herniation. J Neurosurg Spine 14: 268–272.

41. He J, Baum LG. 2004. Presentation of galectin-1 by extra-cellular matrix triggers T cell death. J Biol Chem 279: 4705–4712.

42. Flores-Ibarra A, Vértesy S, Medrano FJ, et al. 2018. Crystalization of a human galectin-3 variant with two ordered segments in the shortened N-terminal tail. Sci Rep 8:9835.

43. Colnot C, Sidhu SS, Balmain N, Poirier F. 2001. Uncoupling of chondrocyte death and vascular invasion in mouse galectin-3 null mutant bones. Dev Biol 229:203–214.

44. Guévermont M, Martel-Pelletier J, Boileau C, et al. 2004. Galectin-3 surface expression on human adult chondrocytes: a potential substrate for collagenase-3. Ann Rheum Dis 63: 636–643.

45. Manning JC, García Caballero G, Knospe C, et al. 2017. Network analysis of adhesion/growth-regulatory galectins and their binding sites in adult chicken retina and chordoid. J Anat 231:23–37.

46. Zivcovic V, Broz P, Flik Z, et al. 2017. Genome-wide expression profiling (with focus on the galectin network) in tumor, transition zone and normal tissue of head and neck cancer: marked differences between individual patients and the site of specimen origin. Anticancer Res 37:2275–2288.

47. Manning JC, García Caballero G, Knospe C, et al. 2018. Three-step monitoring of glycans and galectin profiles in the anterior segment of the adult chicken eye. Ann Anat 217:66–81.

48. Manning JC, Caballero GG, Ruiz FM, et al. 2018. Members of the galectin network with deviations from the canonical sequence signature. 2. Galectin-related protein (GRP). Trends Glycosci Glycotechnol 30:SE11–SE137.

49. Ludvig A-K, Michalak M, Xiao Q, et al. 2019. Design-functionality relationships for adhesion/growth-regulatory galectins. Proc Natl Acad Sci USA 116:2837–2842.

50. Iwaki J, Hirabayashi J. 2018. Carbohydrate engineering. Tissue Eng 9:667–674.